On July 7, Kailera Therapeutics announced that its GLP-1 drug for diabetes and obesity met the primary endpoints in two late-stage trials. On the same day, the U.S. Food and Drug Administration approved Vera Therapeutics' drug to treat a potentially life-threatening kidney disease. On July 9, Dr. Reddy's Laboratories announced a delay in commercial supplies of semaglutide due to an issue with the active pharmaceutical ingredient.
